Loading...
NPI 1285682591 · Brunswick, ME · Physiological Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Maine Molecular Imaging LLC is a physiological laboratory provider located in Brunswick, Maine. This profile covers 3 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Maine Molecular Imaging LLC |
| Address | 123 Medical Center Dr |
| City | Brunswick |
| State | ME |
| ZIP | 04011 |
| Taxonomy | Physiological Laboratory |
| NPI Enumerated | May 5, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $492.7K |
| Medicaid | $27.9K |
MAINE MOLECULAR IMAGING LLC is a specialized PET/CT imaging and radiopharmaceutical provider within the Physiological Laboratory taxonomy, with billing concentrated in PET/CT procedure codes (78815, 78816) and the FDG radiopharmaceutical supply code (A9552). The top three Medicare codes (78815, A9552, 78816) together account for 100.0% of the provider's Medicare revenue, indicating an operation focused squarely on diagnostic PET imaging and associated tracer supply rather than a broader mix of clinical services.
Revenue is heavily Medicare-weighted: total Medicare revenue is $492.7K versus total Medicaid revenue of $27.9K, so Medicare comprises the dominant share of billings for this entity. The Medicaid footprint is present but small in absolute scale relative to Medicare, consistent with a practice that primarily serves the Medicare population or contracts where Medicare is the principal payer.
Medicare revenue concentration is extreme at the code level: 78815 alone generates $312.8K (63.5% of this provider's total Medicare revenue), A9552 accounts for $130K (26.4%), and 78816 contributes $50.1K (10.2%); precomputed top-3 codes account for 100.0% of Medicare revenue. This tight concentration around PET/CT and the FDG dose suggests limited service-line diversification and reliance on a narrow set of high-value imaging services.
Medicaid billing shows a similar concentration: the top Medicaid codes 78815 and A9552 together account for 100.0% of Medicaid revenue, with 78815 making up $19.2K (69.1% of this provider's total Medicaid revenue) and A9552 $8.6K (30.9%). Medicaid average paid amounts are lower than Medicare for the same items (e.g., A9552 is $414 avg paid/claim in Medicare vs $139 avg paid/claim in Medicaid; 78815 is $1167 avg in Medicare vs $377 avg in Medicaid), highlighting material payer rate differences on identical services.
Competitive standing for Medicare shows a modest-to-strong national presence on select codes: 78815 ranks #726 of 6566 providers nationally (89th percentile), A9552 ranks #163 of 2411 (93th percentile), and 78816 ranks #586 of 1983 (70th percentile). Despite these percentile placements, each Medicare code is described as a typical, unremarkable volume for the code, implying that while the provider sits above many peers on certain ranks, its activity is not flagged as an outlier in clinical billing patterns.
State-level Medicaid competitiveness is limited. For 78815 the provider ranks #11 of 12 in-state (9th percentile; typical, unremarkable volume for this code) and for A9552 it ranks #8 of 8 in-state (0th percentile; typical, unremarkable volume for this code), indicating the practice is a minor participant in Maine's Medicaid PET/CT market.
The financial profile reflects bundled service delivery: sizable per-claim Medicare payments for imaging (78815 $1167 avg paid/claim) plus revenue from the radiopharmaceutical (A9552 $414 avg paid/claim) together drive the bulk of Medicare receipts. This mix is consistent with a business model that combines imaging procedure reimbursement with tracer supply revenue rather than large claim volumes across many CPTs.
The provider has long tenure on file, with NPI enumerated 2006-05-05 (~20 years ago), supporting the interpretation that this is an established imaging operation rather than a recent entrant; longevity may affect referral patterns, contracting leverage with payers, and local recognition despite modest Medicaid market share.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 270 | $1,170 | $312.8K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 310 | $410 | $130K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 40 | $1,170 | $50.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 50 | $380 | $19.2K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 60 | $140 | $8.6K |
How this provider's Medicaid billing volume and revenue compare to other Maine providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Maine median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 11 | 10 | 640 | $400 | $451.6K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 8 | 10 | 590 | $20 | $26.3K |
Other providers in the same ZIP code as Maine Molecular Imaging LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.